Barrier products

Barrier preparations are available as ointments, creams and films. Medicines optimisation projects in this area focus on using products appropriately and avoiding waste.

Key recommendations

- The indications, mode of use and frequency of reapplication of different barrier preparations vary, so it is important to follow the individual manufacturer's instructions.¹
- Barrier preparations have a role in preventing and managing skin damage due to moisture and irritants. This can be due to:
- » Urinary and/or faecal incontinence.^{2,3}
- » Chronic venous leg ulcers and other wounds. 1,4
- » Perspiration in skin folds.1
- » Presence of a stoma.⁵
- Do not use barrier creams as sole protection against contact with allergens.⁶
- Choose a barrier product that does not reduce the effectiveness of other interventions. Some products (particularly oil-based) can impede dressing or tape adhesion and interfere with the absorption capability of continence pads.¹
- Do not use barrier preparations in isolation, but rather as part of a strategy that includes risk assessment and an appraisal of the underlying issue.⁷
- Consider the need for an assessment of continence, stoma or wound care where barrier preparations are requested, particularly repeatedly.¹
- Local formularies can support prescribers in making appropriate, costeffective barrier preparation choices. Formularies should include information about product suitability and specific instructions for product use.
- Prescriptions and dispensing labels should also include specific instructions for product use. Avoid non-specific instructions (e.g. 'as directed').
- Ensure GP practices have a process in place for identifying and investigating prescriptions for non-formulary barrier products or excessive quantities.
- Barrier creams and ointments for nappy rash should be purchased over-the-counter (OTC) with advice from an appropriate health care professional.
 This could be a health visitor, pharmacist or a GP, depending on the severity of the nappy rash.⁸

Supporting evidence

The National Institute of Health and Care Excellence (NICE) identified limited, low quality evidence in to support the use of barrier preparations for the prevention and management of pressure ulcers. They recommend considering a barrier preparation for the prevention of skin damage in those at high risk of developing a moisture lesion or incontinence-associated dermatitis, as identified by skin assessment.²

NICE recommend that people with faecal incontinence are offered skin care advice that covers both cleansing and barrier products. This is based on evidence from two randomised controlled trials and one cohort study.³

The evidence for the use of barrier creams in preventing irritant contact dermatitis is conflicting.⁶ Their value in this indication has been questioned.⁹

Specific guidelines on the use of barrier preparations in those with a stoma are not available. However they have an accepted role in managing sore skin around stoma sites.

Savings

In England and Wales £33.3 million is spent annually on barrier creams and films (ePACT Sep 2016 - Nov 2016).

A 20% reduction in prescribing of barrier preparations (excluding nappy rash barrier products) would produce savings in the order of £6.2 million annually. This equates to £10,113 per 100,000 patients. This may be achieved by choosing the most cost effective and appropriate products, and by reducing wastage and inappropriate prescribing.

An 80% reduction in prescribing of nappy rash barrier products (by promoting OTC purchase) would produce savings in the order of £2 million annually. This equates to £3,198 per 100,000 patients.

References

- 1. Best Practice Statement. Care of the Older Person's Skin. London: Wounds UK, 2012 (Second edition). Accessed 09/08/16 via www.wounds-uk.com
- 2. National Clinical Guideline Centre. Pressure ulcer prevention. The prevention and management of pressure ulcers in primary and secondary care (full NICE guideline) [CG179]. National Institute for Health and Care Excellence. Issued April 2012. Accessed 09/02/16 via www.nice.org.uk/guidance/cg179/evidence
- 3. National Collaborating Centre for Acute Care (2007). Faecal incontinence: The management of faecal incontinence in adults (full NICE guideline) [CG49]. National Institute for Health and Care Excellence. Issued June 2007. Accessed 19/7/16 via www.nice.org.uk/guidance/cg49/evidence
- 4. Scottish Intercollegiate Guidelines Network (SIGN). Management of chronic venous leg ulcers (Guideline 120). August 2010. Accessed 13/08/16 via www.sign.ac.uk/pdf/sign120.pdf
- 5. Burch J. When to use a barrier cream in patients with a stoma. British Journal of Nursing 2013 (Stoma care supplement);22(5):S12.
- 6. National Institute for Health and Care Excellence. Clinical Knowledge Summary, Dermatitis contact. Last updated March 2013. Accessed13/08/16 via cks.nice.org.uk/dermatitis-contact
- 7. All Wales Tissue Viability Nurse Forum and All Wales Continence Forum. All Wales Best Practice Statement on the Prevention and Management of Moisture Lesions. Issued 2014. Accessed 10/08/16 via www.welshwoundnetwork.org/files/5514/0326/4395/All_Wales-Moisture_Lesions_final_final.pdf
- 8. NHS Choices Nappy rash. Last reviewed 30/09/15. Accessed 06/09/16 via www.nhs.uk/Conditions/pregnancy-and-baby/Pages/Nappy-rash.aspx
- 9. Bourke J, Coulson I. Guidelines for the management of contact dermatitis: an update. British Journal of Dermatology 2009;160:946-954.

Contact help@prescgipp.info with any queries or comments related to the content of this document.

This document represents the view of PrescQIPP CIC at the time of publication, which was arrived at after careful consideration of the referenced evidence, and in accordance with PrescQIPP's quality assurance framework.

The use and application of this guidance does not override the individual responsibility of health and social care professionals to make decisions appropriate to local need and the circumstances of individual patients (in consultation with the patient and/or guardian or carer). Terms and conditions

Additional resources available: https://www.prescqipp.info/category/367-barrier-products



Bulletin



Data pack



Product summary and pathway

